Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
BMC Cancer. 2017 Aug 23;17(1):562. doi: 10.1186/s12885-017-3538-4.
Vitamin D Life suspects that this trial will be successful AND that a similar amount of vitamin D will PREVENT malignant melanoma
- Melanoma is 44 percent LESS LIKELY if get sun on the job – Nov 2013
- Vitamin D protects DNA against UV skin damage – 5 studies 2012-2013
- Skin cancer (in mice) due to UV was prevented by vitamin D (active, topical) – June 2016
- People with metastatic melanoma and initially Vitamin D deficient had 4.7 times worse outcome if not get enough D – Dec 2016
- Overview Cancer and vitamin D
- Cancer risk reduced 65 percent by vitamin D levels greater than 40 nanograms – April 2016
Cancer category starts with the following
- Cancer
211 items Overview Cancer and vitamin D - After Cancer Diagnosis
84 items - Bladder Cancer
25 items - Breast Cancer
223 items Overview Breast Cancer and Vitamin D - Colon Cancer
116 items Overview Cancer-Colon and vitamin D - Leukemia
16 items - Liver Cancer
14 items - Lung Cancer
49 items Overview Lung cancer and vitamin D - Lymphoma Cancer
22 items - Other Cancer
55 items - Ovarian Cancer
21 items - Pancreatic Cancer
55 items - Prostate Cancer
92 items Prostate Cancer and Vitamin D studies - Skin Cancer
110 items Overview Suntans melanoma and vitamin D - Cancer incidence and mortality is decreased if 40-60 ng of Vitamin D – April 2019
- Vitamin D Reduces Cancer Risk - Why Scientists Accept It but Physicians Do Not - Feb 2019
- Vitamin D prevents breast cancer, reduces BC mortality, and reduces BC chemotherapy problems – Sept 2018
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- Diagnosed with breast cancer – take vitamin D to cut chance of death by half – July 2018
- Pancreatic cancer 55 percent less likely if optimal vitamin D (vs low) – Nov 2017
- Melanoma 25 X more likely if low vitamin D – Feb 2018
- Better Cancer survival if higher vitamin D a decade earlier (esp. Melanoma, Kidney, Prostate)– Aug 2018
Cancers get less Vitamin D when there is a poor Vitamin D Receptor
- Cancer and the Vitamin D Receptor, a primer – Sept 2017
- Cancer is leading cause of death - Vitamin D and Receptor activators help
- Risk of Cancer increased if poor Vitamin D Receptor – meta-analysis of 73 studies Jan 2016
- Cancer (general) and VDR
15 articles - Breast Cancer and VDR
15 articles - Colon Cancer and VDR
9 articles - Prostate Cancer and VDR
6 articles - Skin Cancer and VDR
10 articles - Note some Health problems, such as some Cancers, protect themselves by actively reducing Receptor activation
 Download the PDF from Vitamin D LifeBACKGROUND:
Previous studies have investigated the protective effect of vitamin D serum levels, at diagnosis and during the follow-up period after treatment, on melanoma outcome. In the present study we assess whether vitamin D supplementation, in the follow-up period after diagnosis and surgical resection of the primary tumor, has a protective effect on relapse of cutaneous malignant melanoma and whether this protective effect correlates with vitamin D levels in serum and Vitamin D Receptor immunoreactivity in the primary tumor.METHODS/DESIGN:
This study is a multicenter randomized double blind placebo- controlled phase III trial. Patients between the age of 18 and 80 years diagnosed and treated surgically for a melanoma stage IB-III are eligible for randomization in a 1:1 ratio to active treatment or placebo. The study drug is taken each month and consists of either 100,000 International Unit cholecalciferol or arachidis oleum raffinatum used as a placebo. The primary endpoint is relapse free survival. The secondary endpoints are 25 hydroxyvitamin D3 serum levels at diagnosis and at 6 month intervals, melanoma subtype, melanoma site and stage of melanoma at diagnosis according to the 2009 American Joint Committee on Cancer melanoma staging and classification. At randomization a bloodsample is taken for DNA analysis. The study is approved by the local Ethics Committees.DISCUSSION:
If we can confirm our hypothesis that vitamin D supplementation after removal of the tumor has a protective effect on relapse of cutaneous malignant melanoma we may reduce the burden of CMM at several levels. Patients, diagnosed with melanoma may have a better clinical outcome and improved quality of life. There will be a decrease in health care costs related to treatment of metastatic disease and there will be a decrease in loss of professional years, which will markedly reduce the economic burden of the disease.TRIAL REGISTRATION: Clinical Trial.gov, NCT01748448 , 05/12/2012.
PMID: 28835228 DOI: 10.1186/s12885-017-3538-4
Recurrence of malignant melanoma may be reduced by 100,000 IU of vitamin D monthly – trial underway 2017997 visitors, last modified 25 Aug, 2017, - Breast Cancer and VDR
- After Cancer Diagnosis